Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 51.72 | -48.84 | 36.72 | -- | -- |
| EBIT | -381.87 | -314.37 | -128.26 | -21.52 | -65.29 |
| Net Profit | -379.26 | -310.33 | 10.32 | -22.26 | -39.98 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-21 | Dec-20 |
| EBIT-Margin
| -9,181.96 | -9,181.96 | -8,350.08 | -3,788.03 | -14,575.89 |
| Net Margin
| -19,372.40 | -115,859.20 | -2,199.76 | -- | -10,050.90 |
| Return on equity
| -153.05 | -247.68 | -211.23 | -74.36 | -117.28 |
| Return on Capital
| -90.56 | -128.20 | -- | -56.04 | -72.95 |
| Return on Assets
| -70.97 | -98.80 | -94.92 | -49.71 | -60.85 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.29 | 0.35 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
--
|
-56.04
|
-72.95
|
-142.70
|
-180.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-211.23
Lower than Peers by 184.92
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-211.23
|
-74.36
|
-117.28
|
-267.52
|
-274.54
|
|
Peer Median
|
-26.31
|
--
|
--
|
--
|
--
|
ROA
-94.92
Lower than Peers by 81.95
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-94.92
|
-49.71
|
-60.85
|
-102.35
|
-131.49
|
|
Peer Median
|
-12.96
|
--
|
--
|
--
|
--
|
EBIT Margin
-8,350.08
Lower than Peers by 8,290.37
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-8,350.08
|
-3,788.03
|
-14,575.89
|
--
|
--
|
|
Peer Median
|
-59.70
|
--
|
--
|
--
|
--
|
Net Margin
-2,199.76
Lower than Peers by 2,128.70
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-2,199.76
|
-3,812.10
|
-10,050.90
|
-28,693.89
|
-8,906.30
|
|
Peer Median
|
-71.06
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.01
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-0.01
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
36.72
Higher than Peers by 16.17
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
36.72
|
2.50
|
--
|
--
|
--
|
|
Peer Median
|
20.56
|
--
|
--
|
--
|
--
|
EBIT Growth
-128.26
Lower than Peers by 143.46
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-128.26
|
8.92
|
11.91
|
-6.31
|
-22.89
|
|
Peer Median
|
15.20
|
--
|
--
|
--
|
--
|
Net Profit Growth
-123.23
Lower than Peers by 131.09
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-123.23
|
10.32
|
11.23
|
-6.31
|
-21.48
|
|
Peer Median
|
7.86
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
--
|
0.29
|
0.35
|
1.89
|
0.36
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.24
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
0.24
|
0.16
|
0.15
|
0.61
|
0.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.61
Lower than Peers by 1.88
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
1.61
|
1.04
|
2.46
|
0.42
|
2.07
|
|
Peer Median
|
3.48
|
--
|
--
|
--
|
--
|
Quick Ratio
1.61
Lower than Peers by 1.68
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
1.61
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.29
|
--
|
--
|
--
|
--
|
Interest Coverage
-333.50
Lower than Peers by 331.99
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-333.50
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-1.51
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
16.24
Lower than Peers by 8.09
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
16.24
|
18.60
|
55.36
|
--
|
--
|
|
Peer Median
|
24.33
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.22
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
0.01
|
0.01
|
0.00
|
--
|
--
|
|
Peer Median
|
0.23
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
--
|
62.81
|
202.19
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
--
|
918.63
|
6,664.21
|
63.35
|
42.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
0.16
Lower than Peers by 4.80
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
0.16
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.96
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.10
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
0.10
|
0.06
|
0.59
|
-0.31
|
0.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3
Lower than Peers by 81
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
3
|
--
|
--
|
--
|
--
|
|
Peer Median
|
83
|
--
|
--
|
--
|
--
|